Kaitlyn Whyman

Summary for Physicians: Complex Extensive-Stage Small Cell Lung Cancer Case: Tarlatamab Management Through Toxicity to Clinical Benefit Initial phase: Close inpatient monitoring during early cycles due to risk of cytokine release syndrome (CRS) and immune effector cell –associated neurotoxicity syndrome (ICANS). Gradual dose escalation may be used to improve tolerance.

Summary for Physicians: Future Research Priorities: Optimizing tarlatamab administration: Investigate dose optimization and scheduling to maximize efficacy while minimizing toxicity. Explore combination therapies with other immunotherapies or targeted agents for synergistic effects. Toxicity management: Develop predictive biomarkers for early detection of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.

Summary for Physicians: Best Practices for Transitioning From Inpatient to Outpatient Care: Clear communication: Ensure care coordination between inpatient and outpatient teams for a smooth transition. Provide detailed discharge instructions, including follow-up plans, medications, and warning signs of complications. Outpatient visit frequency: Initially, schedule visits weekly or biweekly post discharge for close monitoring.